Survival curves—VEPEMB patients. (A) OS of VEPEMB-treated patients by stage of disease at diagnosis. Early-stage patients (n = 31) demonstrate OS at 36 months of 80.7%, and advanced-stage patients (n = 72) demonstrate OS at 36 months of 66.2%. There is no significant difference in OS between the groups (P = .308, log-rank). (B) Disease-specific survival for VEPEMB-treated patients by stage of disease at diagnosis. There is no difference in outcome in OS with HL as cause of death between early-stage (n = 31; 90.3%) and advanced-stage (n = 72; 82.8%) at 36 months (P = .853, log-rank). (C) Disease-specific survival of VEPEMB-treated patients stratified by response to initial therapy. Survival for patients achieving CR (n = 67) on VEPEMB at 36 months was 98.4% and is significantly different (P = .001, log rank) from those with PR (n = 18 with 10 HL deaths) and NR/PD (n = 5 with 3 HL deaths) where survival was 47.5% and 40%, respectively. (D) PFS for VEPEMB-treated patients by stage of disease at presentation. Intention-to-treat PFS for whole VEPEMB cohort (n = 103) for early and advanced stages demonstrates PFS of 74% and 58%, respectively, at 36 months. Thirteen patients were not assessable for response. Eighteen PR patients and 5 NR/PD patients account for early events in these curves.